Aytu BioPharma's GAAP loss for 6 months of fiscal year 2022 was $39.399 million, up 2.8 times from $13.831 million in the previous year. Revenue increased 57.1% to $45.022 million from $28.667 million a year earlier.
Aytu BioPharma's GAAP loss for 6 months of fiscal year 2022 was $39.399 million, up 2.8 times from $13.831 million in the previous year. Revenue increased 57.1% to $45.022 million from $28.667 million a year earlier. 
irdirect.net
English (US) 